rss
Postgrad Med J 2009;85:141-147 doi:10.1136/pgmj.2008.072439
  • Review

Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease

  1. P N Black1,
  2. C F McDonald2
  1. 1
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, New Zealand
  2. 2
    Department of Respiratory and Sleep Medicine, Institute for Breathing and Sleep, Austin Hospital, Melbourne, Australia
  1. Dr P Black, Department of Pharmacology and Clinical Pharmacology, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand; pn.black{at}auckland.ac.nz
  • Received 31 August 2008
  • Accepted 3 January 2009

Abstract

Frequent exacerbations of chronic obstructive pulmonary disease (COPD) are associated with impaired quality of life, and hospital admissions for exacerbations account for a large proportion of the expenditure of COPD. An important objective when treating COPD is to reduce the frequency of exacerbations. Studies published in the last few years have increased our knowledge on how to prevent exacerbations, but a number of questions remain unanswered. Tiotropium, inhaled steroids and long-acting inhaled β agonists reduce the frequency of exacerbations, but further studies are necessary to determine if combining tiotropium with the other inhaled medicines is more effective than using them separately. There is evidence that mucolytics and prophylactic antibiotics reduce exacerbations, but there is uncertainty how these treatments should be used. Both influenza and pneumococcal vaccination are recommended in guidelines, although evidence for the latter remains controversial. Other interventions including oral bacterial extracts and self-management programmes warrant further study.

Footnotes

  • Funding: None.

  • Competing interests: PB has undertaken contract research and/or received support for travel from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Sanofi Aventis. CM has received support for lectures or conference travel from Boehringer Ingelheim, GlaxoSmithKline and Astra Zeneca. She has participated in Advisory Boards for Pfizer, GlaxoSmithKline and Boehringer Ingelheim.

This Article

Services

  1. Request permissions

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of PMJ.
View free sample issue >>

Free archive
The full back archive is now available for PMJ. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.